Back to top
more

Cue Biopharma (CUE)

(Delayed Data from NSDQ)

$1.65 USD

1.65
790,501

-0.06 (-3.51%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $1.65 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Alnylam (ALNY) delivered earnings and revenue surprises of 0% and 5.37%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cue Biopharma (CUE) delivered earnings and revenue surprises of 31.03% and 137.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 8.11% and 37.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -5.45% and 18.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of 13.11% and 4.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks

by Zacks Equity Research

Cue Biopharma (CUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Cue Biopharma (CUE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -50% and 13.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of 18.52% and 1.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?

by Zacks Equity Research

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?

by Zacks Equity Research

Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year.

Acadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Harmony Biosciences Holdings, Inc. (HRMY) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of -9.68% and 3.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cue Biopharma, Inc. (CUE) delivered earnings and revenue surprises of 12.12% and 37.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -37.50% and 11.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.51% and 8.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Cue Biopharma, Inc. (CUE) Looks Ripe for Bottom Fishing

by Zacks Equity Research

Cue Biopharma, Inc. (CUE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of 34.83% and 2.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -22.68% and 49.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Universal Health (UHS) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Universal Health Services' (UHS) first-quarter results are likely to reflect the benefits of increased admissions.